TP53 and ovarian cancer: Although no targeted therapies are yet available for these TP53 mutations, in a recent study, tumor infiltrating T‐cell responses to two TP53 hotspot mutations G245S and Y220C were identified in the context of HLA‐DRB3*02:02 in two separate ovarian cancer patients.20 Among the tumors sequenced in this cohort, five harbored the TP53 Y220C mutation and one had the G245S mutation.